Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA269929
Max Phase: Preclinical
Molecular Formula: C23H22O3
Molecular Weight: 346.43
Molecule Type: Small molecule
Associated Items:
ID: ALA269929
Max Phase: Preclinical
Molecular Formula: C23H22O3
Molecular Weight: 346.43
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C=CCOc1ccc(/C=C/C(=O)/C=C/c2ccc(OCC=C)cc2)cc1
Standard InChI: InChI=1S/C23H22O3/c1-3-17-25-22-13-7-19(8-14-22)5-11-21(24)12-6-20-9-15-23(16-10-20)26-18-4-2/h3-16H,1-2,17-18H2/b11-5+,12-6+
Standard InChI Key: HMZANBKZFJOKDD-YDWXAUTNSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 346.43 | Molecular Weight (Monoisotopic): 346.1569 | AlogP: 5.11 | #Rotatable Bonds: 10 |
Polar Surface Area: 35.53 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 0 |
#RO5 Violations: 1 | HBA (Lipinski): 3 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 5.97 | CX LogD: 5.97 |
Aromatic Rings: 2 | Heavy Atoms: 26 | QED Weighted: 0.44 | Np Likeness Score: 0.06 |
1. Liang G, Li X, Chen L, Yang S, Wu X, Studer E, Gurley E, Hylemon PB, Ye F, Li Y, Zhou H.. (2008) Synthesis and anti-inflammatory activities of mono-carbonyl analogues of curcumin., 18 (4): [PMID:18234497] [10.1016/j.bmcl.2007.12.068] |
2. Liang G, Shao L, Wang Y, Zhao C, Chu Y, Xiao J, Zhao Y, Li X, Yang S.. (2009) Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents., 17 (6): [PMID:19243951] [10.1016/j.bmc.2008.10.044] |
3. Lin H, Hu GX, Guo J, Ge Y, Liang G, Lian QQ, Chu Y, Yuan X, Huang P, Ge RS.. (2013) Mono-carbonyl curcumin analogues as 11β-hydroxysteroid dehydrogenase 1 inhibitors., 23 (15): [PMID:23800686] [10.1016/j.bmcl.2013.05.080] |
4. Liu Z, Tang L, Zou P, Zhang Y, Wang Z, Fang Q, Jiang L, Chen G, Xu Z, Zhang H, Liang G.. (2014) Synthesis and biological evaluation of allylated and prenylated mono-carbonyl analogs of curcumin as anti-inflammatory agents., 74 [PMID:24321865] [10.1016/j.ejmech.2013.10.061] |
Source(1):